Short answer · Medically reviewed summary · Last updated: 2026-04-07
Intracranial Hypertension, historically termed "pseudotumor cerebri," was first described in the late 19th century as a condition mimicking brain tumors despite the absence of a mass. Over the last 130 years, our understanding has shifted from viewing Intracranial Hypertension as a mysterious, benign ailment to recognizing it as a complex, potentially sight-threatening neurological disorder that requires multidisciplinary management. Who first identified Intracranial Hypertension? The clinical picture of Intracranial Hypertension was first documented by German physician Heinrich Quincke in 1893.
8 people with Intracranial Hypertension have shared their first-person experience on this question at DiseaseMaps.
What is the history of Intracranial Hypertension?
History of Intracranial Hypertension: when and how it was discovered, and the milestones in research since, medically reviewed.
Intracranial Hypertension, historically termed "pseudotumor cerebri," was first described in the late 19th century as a condition mimicking brain tumors despite the absence of a mass. Over the last 130 years, our understanding has shifted from viewing Intracranial Hypertension as a mysterious, benign ailment to recognizing it as a complex, potentially sight-threatening neurological disorder that requires multidisciplinary management.
Who first identified Intracranial Hypertension?
The clinical picture of Intracranial Hypertension was first documented by German physician Heinrich Quincke in 1893. He described patients who presented with severe headaches and papilledema (swelling of the optic nerve) that resembled the symptoms of a brain tumor, yet the patients did not have a space-occupying lesion. In 1904, Max Nonne further refined this by describing the condition as "pseudotumor cerebri," a term that persisted in medical literature for decades because it accurately captured the diagnostic challenge: the patient appeared to have a tumor, but imaging or surgery revealed none.
How has our understanding of Intracranial Hypertension evolved?
For much of the 20th century, Intracranial Hypertension was often dismissed as a benign or self-limiting condition. However, clinicians eventually realized that the chronic pressure on the optic nerves could lead to permanent vision loss, shifting the medical consensus toward aggressive monitoring. Today, we understand that Intracranial Hypertension is often idiopathic (of unknown cause), though it is frequently associated with specific factors such as obesity, certain medications, and venous sinus stenosis. The evolution of neuroimaging, particularly MRI and MR venography, has been critical in allowing physicians to visualize the brain’s venous drainage systems, revealing that narrowed veins in the skull often play a central role in the condition.
What were the historical milestones in treatment?
The management of Intracranial Hypertension has progressed from rudimentary interventions to highly specialized neurosurgical procedures. Historically, serial lumbar punctures were the primary method for relieving acute pressure. Over time, the medical community standardized the following treatment hierarchy:
- Pharmacological intervention: The introduction of carbonic anhydrase inhibitors (such as acetazolamide) became the gold standard for reducing cerebrospinal fluid production.
- Surgical shunting: In the mid-20th century, ventriculoperitoneal and lumboperitoneal shunts were developed to divert excess fluid.
- Venous stenting: In recent decades, minimally invasive endovascular stenting has emerged as a successful treatment for patients with identified venous sinus stenosis.
How did patient advocacy change the medical landscape?
Historically, patients with Intracranial Hypertension often faced skepticism due to the "hidden" nature of the disease, as symptoms like pulsatile tinnitus and chronic fatigue are not always visible on standard scans. The rise of digital communities, such as the 2,580 members currently connected via DiseaseMaps.org, has been transformative. These platforms have empowered patients to advocate for earlier ophthalmological screenings and faster access to neurology specialists, ensuring that the patient voice is now a driving force in clinical research and awareness campaigns.
Next steps
- Consult a neurologist or neuro-ophthalmologist to discuss your specific symptoms and vision monitoring.
- Keep a detailed headache and symptom diary to share during clinical evaluations.
- Join the DiseaseMaps.org community to connect with other patients and share lived experiences regarding treatments and symptom management.
- Request a referral to a center specializing in neurovascular conditions if you are considering surgical options like venous stenting.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.
References
- National Institute of Neurological Disorders and Stroke (NINDS): Idiopathic Intracranial Hypertension Information Page.
- Orphanet: Rare Disease Database (ORPHA: 457).
- NIH Genetic and Rare Diseases (GARD) Information Center.
- The International Headache Society: Classification and diagnostic criteria for headache disorders.
Posted Aug 15, 2017 by Mommy2Five 1500
Posted Aug 18, 2017 by Unique cheatom 2120
Posted Oct 18, 2017 by Sara 2000
The terms "benign" and "pseudotumor" derive from the fact that increased intracranial pressure may be associated with brain tumors. Those patients in whom no tumour was found were therefore diagnosed with "pseudotumor cerebri" (a disease mimicking a brain tumor). The disease was renamed benign intracranial hypertension in 1955 to distinguish it from intracranial hypertension due to life-threatening diseases (such as cancer);[20] however, this was also felt to be misleading because any disease that can blind someone should not be thought of as benign, and the name was therefore revised in 1989 to "idiopathic (of no identifiable cause) intracranial hypertension".[21][22]
Shunt surgery was introduced in 1949; initially, ventriculoperitoneal shunts were used. In 1971, good results were reported with lumboperitoneal shunting. Negative reports on shunting in the 1980s led to a brief period (1988–1993) during which optic nerve fenestration (which had initially been described in an unrelated condition in 1871) was more popular. Since then, shunting is recommended predominantly, with occasional exceptions.[1
Posted Oct 19, 2017 by Julie 2000
The terms "benign" and "pseudotumor" derive from the fact that increased intracranial pressure may be associated with brain tumors. Those patients in whom no tumor was found were therefore diagnosed with "pseudotumor cerebri" (a disease mimicking a brain tumor). The disease was renamed benign intracranial hypertension in 1955 to distinguish it from intracranial hypertension due to life-threatening diseases (such as cancer);[20] however, this was also felt to be misleading because any disease that can blind someone should not be thought of as benign, and the name was therefore revised in 1989 to "idiopathic (of no identifiable cause) intracranial hypertension".[21][22]
Shunt surgery was introduced in 1949; initially, ventriculoperitoneal shunts were used. In 1971, good results were reported with lumboperitoneal shunting. Negative reports on shunting in the 1980s led to a brief period (1988–1993) during which optic nerve fenestration (which had initially been described in an unrelated condition in 1871) was more popular. Since then, shunting is recommended predominantly, with occasional exceptions.
Posted Oct 28, 2017 by lisa 3365
Posted Oct 29, 2017 by So 2000
Before we had antibiotic therapy, middle ear infections occasionally would trigger intracranial inflammation and the disease was called Otitic Hydrocephalus.
The term "pseudotumor cerebri" was introduced in 1904 by Quinche's compatriot Max Nonne.
The term "pseudotumor" come from the fact that increased intracranial pressure may be associated with brain tumors, however as no tumour was found patients were therefore diagnosed with "pseudotumor cerebri" (a disease mimicking a brain tumor).
In 1931 Symonds was the first to suggest that it was caused by dural sinus obstruction.
Diagnostic criteria for IIH were developed in 1937 by the Baltimore neurosurgeon Walter Dandy; Dandy also introduced subtemporal decompressive surgery in the treatment of the condition.
The disease was renamed benign intracranial hypertension in 1955 to distinguish it from intracranial hypertension due to life-threatening diseases (such as cancer); however, this was also felt to be misleading because any disease that can blind someone should not be thought of as benign, and the name was therefore revised in 1989 to "idiopathic (of no identifiable cause) intracranial hypertension".
Posted Feb 18, 2018 by Kelly 2560
Posted Jun 7, 2017 by Lo 2000
